ArticleNeural regeneration research2026
Neuromodulation techniques targeting neurotransmitter dysfunction: Innovation in treatments for Alzheimer's disease.
Article in Neural regeneration research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute taVNS modulates lateralized hypoactivity in the right cerebral hemisphere in individuals with subjective cognitive decline.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline, synaptic dysfunction, and neurotransmitter imbalance. Novel neuromodulation approaches, both non-invasive and invasive, show promising potential for restoring neural circuit integrity and improving cognition. This review aims to elucidate the relationship between neuromodulation, neural network circuits, and neurotransmitters. It systematically synthesizes recent advances in neuromodulation techniques, focusing on their ability to modulate four critical neurotransmitter systems: cholinergic, glutamatergic, GABAergic, and monoaminergic systems. Additionally, this review establishes a critical association between neurotransmitter regulation and synaptic plasticity mechanisms, proposing a novel "circuit-transmitter" triad framework for intervention. It represents the first systematic integration of the neurotransmitter regulation mechanisms of various neuromodulation techniques while evaluating their clinical viability for Alzheimer's disease intervention. Beyond established targets, this review identifies the hippocampus-thalamus axis, linked via direct entorhinal-thalamic projections, as a promising focus for ultrasonic neuromodulation research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.